Axsome to narrow focus of depression drug trial after limited success in initial run

Market Closed – Nasdaq			5-day change	1st Jan Change
116.63 ^USD	-1.60%		-9.71%	+37.84%

April 01, 2025 at 08:18 am EDT

This article is reserved for members

Unlock the article: REGISTER NOW!

Axsome to narrow focus of depression drug trial after limited success in initial run	08:18am	RE
Axsome’s depression treatment fails to meet main goal of late-stage study	07:10am	RE
Axsome Therapeutics, Inc. Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder with and Without Excessive Daytime Sleepiness	07:00am	CI
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating	Mar. 26	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	Mar. 25	MT
Axsome Therapeutics’ Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint	Mar. 25	MT
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint	Mar. 25	RE
Axsome’s ADHD drug meets main goal in late-stage study	Mar. 25	RE
Axsome Therapeutics’ ADHD drug meets main goal in late-stage study	Mar. 25	RE
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder Achieves Primary Endpoint	Mar. 25	CI
Axsome Therapeutics Resolves Sunosi Patent Case With Hikma	Mar. 05	MT
Axsome Therapeutics Receives FDA Indication in Support of Alzheimer’s Drug Submission	Mar. 03	MT
Axsome Therapeutics, Inc. Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission	Mar. 03	CI
Mizuho Raises Price Target on Axsome Therapeutics to $212 From $195, Maintains Outperform Rating	Feb. 28	MT
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $212 From $195, Maintains Outperform Rating	Feb. 26	MT
Axsome Therapeutics Says Migraine Drug Symbravo Achieves Primary Endpoint in Phase 3 Trial	Feb. 24	MT
Axsome Therapeutics Announces SYMBRAVO® (Meloxicam and Rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inhibitors	Feb. 24	CI
RBC Capital Adjusts Price Target on Axsome Therapeutics to $192 From $143, Keeps Outperform Rating	Feb. 19	MT
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $200 From $176, Maintains Buy Rating	Feb. 19	MT
Truist Securities Raises Price Target on Axsome Therapeutics to $200 From $190, Keeps Buy Rating	Feb. 18	MT
Axsome Therapeutics, Inc., Q4 2024 Earnings Call, Feb 18, 2025	Feb. 18
Axsome Therapeutics Q4 Loss Narrows, Revenue Rises	Feb. 18	MT
Earnings Flash (AXSM) Axsome Therapeutics Reports Q4 Revenue $118.8M, vs. FactSet Est of $118.1M	Feb. 18	MT
Earnings Flash (AXSM) Axsome Therapeutics Reports Q4 Loss $-1.54 Per Share, vs. FactSet Est of $-1.32	Feb. 18	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 18	CI

Duration

Period

AXSM: Dynamic Chart

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company’s two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

More about the company

Sell

Buy

Last Close Price

116.63USD

Average target price

173.24USD

Spread / Average Target

+48.53%

Consensus

Trump says U.S. is getting very close to a nuclear deal with Iran

Aramco to Explore Refinery Upgrade, LNG Stake as Part of $90 Billion Deals With US Heavyweights

VEGOILS-Palm oil tracks down weaker related oils on Dalian, Chicago exchanges

Naver, National Geographic Information Institute Sign Deal to Advance Spatial Tech and Services

INDIA RUPEE-Rupee to struggle on weak Asian cues, ongoing dollar demand

Strathcona Resources Announces Sale Of Montney Business For $2.84 Billion And Acquisition Of Hardisty Rail Terminal

FireFly Metals Hits High-Grade Gold, Copper Mineralization at Canada Project

Lawmaker demands explanation for Trump administration’s ouster of intelligence analysts

Databricks continues M&A spree, will buy Neon for $1 billion in AI-agent push

Trump says U.S. is getting very close to a nuclear deal with Iran

NFT founder stole millions from Bitcoin project, investors allege — TradingView News

Ethereum Foundation Unveils Trillion-Dollar Security Initiative To Boost Network Safety

Aramco to Explore Refinery Upgrade, LNG Stake as Part of $90 Billion Deals With US Heavyweights

VEGOILS-Palm oil tracks down weaker related oils on Dalian, Chicago exchanges

Ethereum Foundation Launches ‘Trillion Dollar Security Initiative’ to Fortify Network

Trump says U.S. is getting very close to a nuclear deal with Iran

Aramco to Explore Refinery Upgrade, LNG Stake as Part of $90 Billion Deals With US Heavyweights

VEGOILS-Palm oil tracks down weaker related oils on Dalian, Chicago exchanges

Naver, National Geographic Information Institute Sign Deal to Advance Spatial Tech and Services

INDIA RUPEE-Rupee to struggle on weak Asian cues, ongoing dollar demand

Strathcona Resources Announces Sale Of Montney Business For $2.84 Billion And Acquisition Of Hardisty Rail Terminal

FireFly Metals Hits High-Grade Gold, Copper Mineralization at Canada Project

Lawmaker demands explanation for Trump administration’s ouster of intelligence analysts

Databricks continues M&A spree, will buy Neon for $1 billion in AI-agent push

Trump says U.S. is getting very close to a nuclear deal with Iran

NFT founder stole millions from Bitcoin project, investors allege — TradingView News

Ethereum Foundation Unveils Trillion-Dollar Security Initiative To Boost Network Safety

Aramco to Explore Refinery Upgrade, LNG Stake as Part of $90 Billion Deals With US Heavyweights

VEGOILS-Palm oil tracks down weaker related oils on Dalian, Chicago exchanges

Ethereum Foundation Launches ‘Trillion Dollar Security Initiative’ to Fortify Network

Axsome to narrow focus of depression drug trial after limited success in initial run

Related Posts

Trump says U.S. is getting very close to a nuclear deal with Iran

NFT founder stole millions from Bitcoin project, investors allege — TradingView News

Ethereum Foundation Unveils Trillion-Dollar Security Initiative To Boost Network Safety

5 things to know before the stock market opens Tuesday, April 1

Why one-time Ethereum bulls say the vibes are seriously deteriorating – DL News

DOGE, ADA Lead Crypto Gains as Bitcoin Inches Towards $85K Ahead of Tariffs Kick-In

Recent Posts

Navigate Site

Axsome to narrow focus of depression drug trial after limited success in initial run

Related Posts

Recent Posts

Navigate Site

Follow Us